scanX
Zydus Life Science

Zydus Life Science

926.65
+2.35
(0.25%)
hide
Key Fundamentals
Add Ratio
Market Cap
93,242.67 Cr
EPS
44.97
PE Ratio
18.56
Dividend Yield
1.19 %
Industry
Healthcare
52 Week High
1,059.05
52 Week Low
795.00
PB Ratio
3.69
Debt to Equity
0.09
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from28 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy+32.14 %
+32.14 %
Hold
Hold+42.86 %
+42.86 %
Sell
Sell+25.00 %
+25.00 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Zydus Lifesciences Loses Wholly-Owned Subsidiary Status of Zydus Foundation After Share Allotment5 days ago
Zydus Foundation ceased to be a wholly-owned subsidiary of Zydus Lifesciences Limited on November 19, 2025, following the allotment of 4,50,000 equity shares to Ramanbhai Foundation, a public charitable trust. Zydus Lifesciences will continue to hold 50,000 equity shares in Zydus Foundation, which had zero income and net worth contribution to the consolidated financial statements for the year ended March 31, 2025.
positive
Zydus Lifesciences Receives USFDA Approval for Prostate Cancer Injection10 days ago
Zydus Lifesciences received final USFDA approval for its Leuprolide Acetate injection used for advanced prostate cancer treatment, enabling entry into a US market worth $69 million in annual sales. The approval brings the company's total USFDA approvals to 427 and follows strong quarterly results with net profit rising 39% year-on-year to ₹1,259 crore.
neutral
Zydus Lifesciences Completes US FDA Inspection at Oncology Injectable Facility with Two ObservationsNov 14, 2025
The US FDA conducted a Pre-Approval Inspection at Zydus Lifesciences' SEZ Oncology Injectable manufacturing site in Ahmedabad from November 4-13, 2025, concluding with two observations and no data integrity issues. The company will work with the FDA to address the observations expeditiously as part of the approval process for their new isolator injectable line.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,780.80
#1 4,27,273.57
40.68
#1 54,729.00
9.71
#1 10,980
2.89
72.13
Divis Laboratories
6,359.00
1,68,811.47
69.05
9,712.00
18.67
2,191
35.10
41.81
Torrent Pharmaceuticals
3,718.40
1,25,847.55
58.80
11,539.40
6.99
1,911
30.46
54.13
Cipla
1,504.00
1,22,116.30
22.73
28,409.50
7.12
5,291
3.71
41.45
Dr Reddys Laboratories
1,226.20
1,02,340.34
#1 18.15
33,741.20
16.73
5,725
-0.38
44.49
Zydus Life Science
926.65
#6 93,242.67
#2 18.56
#5 23,511.00
#3 18.55
#4 4,615
#3 34.60
33.65
Mankind Pharma
2,222.70
91,743.83
52.05
12,744.20
#1 20.90
2,007
-21.05
31.31
Lupin
1,999.60
91,332.63
21.34
22,909.50
13.74
3,306
#1 72.75
50.86
Aurobindo Pharma
1,194.00
69,347.71
20.70
32,345.60
9.43
3,484
3.81
58.49
Alkem Laboratories
5,625.00
67,255.31
28.29
13,458.30
3.70
2,216
10.98
49.85
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
112.02 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
2,269
2,291
2,286
2,300
2,310
2,232
2,360
2,266
2,479
2,127
3,165
3,206
3,197
2,870
2,875
3,547
3,658
3,429
3,271
3,555
3,672
3,462
3,663
3,645
3,551
3,971
6,106
3,590
3,821
3,989
3,993
4,199
4,890
5,089
4,313
4,403
5,526
6,110
5,182
5,181
6,371
6,622
6,147
Expenses
1,792
1,807
1,740
1,768
1,784
1,763
1,841
1,907
2,004
1,909
2,365
2,404
2,399
2,249
2,273
2,738
2,932
2,864
3,009
2,947
3,013
2,724
2,977
2,867
2,916
3,092
2,860
2,895
3,103
3,251
3,319
3,301
4,359
3,650
3,224
3,403
3,903
4,124
3,776
3,882
4,622
4,485
4,142
EBITDA
477
484
546
532
526
468
519
359
476
218
800
802
798
621
601
809
726
565
262
608
658
738
686
779
635
879
3,246
695
718
738
673
898
532
1,439
1,089
1,000
1,623
1,986
1,407
1,299
1,749
2,137
2,005
Operating Profit %
20 %
20 %
23 %
22 %
21 %
20 %
21 %
15 %
17 %
9 %
25 %
24 %
24 %
19 %
20 %
22 %
19 %
16 %
7 %
17 %
17 %
20 %
17 %
20 %
19 %
21 %
22 %
18 %
17 %
17 %
16 %
21 %
10 %
28 %
24 %
22 %
27 %
32 %
26 %
24 %
27 %
31 %
31 %
Depreciation
76
69
73
74
76
84
86
90
114
122
126
147
144
142
148
154
156
172
172
174
179
173
175
176
175
183
177
177
185
181
182
182
179
180
184
195
205
215
234
229
238
238
302
Interest
16
12
13
12
16
14
15
7
10
22
41
13
15
35
36
46
77
89
90
81
83
68
45
27
23
27
30
31
39
34
35
33
28
18
9
20
35
32
25
32
77
85
101
Profit Before Tax
426
519
545
537
498
441
435
324
412
154
712
722
724
570
535
672
606
394
122
457
522
588
524
617
526
777
3,135
598
558
673
648
781
484
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
Tax
69
51
60
97
-74
36
46
-6
20
9
200
168
125
102
107
150
124
69
28
86
108
102
89
89
-210
135
123
87
105
96
122
149
125
195
203
157
304
417
351
158
428
400
449
Net Profit
357
468
485
440
572
405
389
331
393
145
513
553
599
467
428
522
482
325
94
371
414
487
435
528
735
643
3,012
511
453
576
526
631
358
1,134
803
790
1,246
1,483
920
1,026
1,244
1,521
1,239
EPS in ₹
17.11
22.47
6.46
4.21
5.59
3.89
3.71
3.16
3.77
1.35
4.92
5.31
5.77
4.50
4.08
4.99
4.40
2.97
1.05
3.65
3.83
4.43
4.62
5.15
6.64
5.74
29.32
4.89
3.88
5.06
5.15
6.15
2.93
10.74
7.91
7.80
11.69
14.11
9.06
10.17
11.64
14.58
12.51
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
37,202
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,231
12,133
12,189
11,521
12,369
13,134
Current Assets
4,227
4,280
6,022
8,230
8,498
8,715
8,716
12,095
10,008
11,420
17,046
Capital Work in Progress
798
951
1,543
1,527
837
742
783
726
1,201
2,423
2,692
Investments
121
416
435
746
674
765
830
3,288
1,547
1,221
6,408
Other Assets
4,776
5,436
7,488
9,310
9,809
9,950
10,139
11,593
11,488
13,269
14,968
Total Liabilities
9,047
10,551
15,221
18,065
23,483
23,687
23,885
27,795
25,756
29,281
37,202
Current Liabilities
3,285
3,461
5,306
6,083
7,343
8,269
7,861
7,827
5,527
5,340
9,042
Non Current Liabilities
1,342
1,255
2,799
3,047
4,461
3,707
1,094
915
541
1,840
1,802
Total Equity
4,421
5,835
7,116
8,936
11,679
11,710
14,930
19,054
19,688
22,102
26,358
Reserve & Surplus
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,853
Share Capital
102
102
102
102
102
102
102
102
101
101
101
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
178
99
756
-3
-811
399
-91
219
-170
-75
414
Investing Activities
-465
-860
-2,872
-974
-3,977
-1,004
-837
-1,018
1,542
-1,492
-8,377
Operating Activities
994
1,894
1,312
919
1,282
2,932
3,294
2,105
2,689
3,196
6,777
Financing Activities
-351
-935
2,316
52
1,885
-1,528
-2,548
-868
-4,400
-1,779
2,014
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.88 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.98 %
74.99 %
74.99 %
74.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
5.72 %
5.59 %
7.52 %
7.53 %
7.32 %
7.13 %
7.34 %
DIIs
11.11 %
10.43 %
11.22 %
11.78 %
12.78 %
11.92 %
12.94 %
13.69 %
13.60 %
13.23 %
13.09 %
12.79 %
12.63 %
12.64 %
10.65 %
10.65 %
11.01 %
11.13 %
10.86 %
Government
0.19 %
0.07 %
0.07 %
0.07 %
0.08 %
0.08 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.16 %
7.31 %
7.38 %
7.40 %
7.81 %
8.02 %
7.60 %
7.04 %
6.42 %
5.97 %
5.67 %
5.60 %
5.29 %
5.37 %
5.48 %
5.47 %
5.41 %
5.46 %
5.49 %
Others
7.66 %
7.32 %
6.44 %
5.87 %
4.46 %
5.11 %
4.48 %
4.29 %
5.00 %
5.82 %
6.26 %
6.63 %
1.38 %
1.43 %
1.37 %
1.36 %
1.28 %
1.28 %
1.32 %
No of Share Holders
0
2,23,384
3,31,155
3,51,595
3,70,931
4,08,017
4,55,624
4,08,231
3,70,396
3,11,764
2,97,953
3,06,495
2,94,324
3,36,309
3,70,863
3,65,356
3,71,619
3,86,127
3,96,105

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3.2 3.5 3.5 3.5 3.5 2.5 6 3 11
Dividend Yield (%) 0.00 0.85 1.01 1.31 0.79 1 0.51 0.6 0.34 1.19

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jul 2021 DIVIDEND Dividend
₹ 3.50 /share
 28 Jul 2021 628.10 571.90
29 Jul 2022 DIVIDEND Dividend
₹ 2.50 /share
 28 Jul 2022 338.75 349.60
28 Jul 2023 DIVIDEND Dividend
₹ 6.00 /share
 28 Jul 2023 518.80 649.50
26 Jul 2024 DIVIDEND Dividend
₹ 3.00 /share
 26 Jul 2024 1,009.00 1,205.80
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 09 Aug 2024 1,009.00 1,279.40
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Nov 2024 1,002.20 968.55
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Feb 2025 995.50 974.00
20 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 20 May 2025 873.70 911.40
25 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
 25 Jul 2025 902.70 971.05
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Aug 2025 969.80 955.50
12 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 12 Aug 2025 911.40 955.50
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2025 1,001.35 971.70

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
General Update5 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations 20157 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Announcement under Regulation 30 (LODR)-Raising of FundsNov 06, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Unaudited Financial Results For The Quarter And Half Year Ended On September 30 2025Nov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Update on board meetingNov 03, 2025
Demand Notice From GST DepartmentNov 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 29, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30 2025.Oct 29, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2025
UpdateOct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 30, 2025
Closure of Trading WindowSep 27, 2025
Receipt Of Order From Commissioner Of CGST AhmedabadSep 25, 2025
Transcript Of The 30Th Annual General MeetingSep 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 05, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Large & Mid Cap Fund Direct Plan-Growth
0.00%
-941543
-0.38%
-0.44%
Parag Parikh Flexi Cap Fund Direct-Growth
1.22%
611478
-0.02%
-0.04%
ICICI Prudential Large Cap Fund Direct-Growth
0.41%
-450292
-0.08%
-0.17%
Sundaram Aggressive Hybrid Fund Direct-Growth
0.00%
-432010
-0.61%
-0.63%
Sundaram Mid Cap Fund Direct-Growth
0.32%
-404251
-0.33%
-0.48%
Kotak Arbitrage Fund Direct-Growth
0.12%
-389700
-0.06%
0.08%
Baroda BNP Paribas Midcap Fund Direct-Growth
0.00%
-350000
-1.57%
-1.59%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.05%
-330146
-0.23%
-0.43%
ICICI Prudential Bharat Consumption Fund Direct - Growth
0.00%
-267824
-0.83%
-0.96%
Nippon India Pharma Fund Direct-Growth
0.00%
-194016
-0.23%
-2.35%
Sundaram Multi Asset Allocation Fund Direct - Growth
0.00%
-160000
-0.56%
-0.59%
Sundaram Balanced Advantage Fund Direct-Growth
0.00%
-92306
-0.54%
-0.55%
Axis Equity Savings Fund Direct-Growth
0.00%
-83700
-0.88%
-0.87%
Kotak Quant Fund Direct - Growth
1.59%
68342
1.16%
1.59%
Baroda BNP Paribas Business Conglomerates Fund Direct-Growth
1.25%
63000
0.78%
1.25%
Bandhan Arbitrage Fund Direct-Growth
0.00%
-59400
-0.07%
0.00%
Mirae Asset Arbitrage Fund Direct - Growth
0.43%
55800
0.13%
0.33%
ICICI Prudential Equity Arbitrage Direct-Growth
0.02%
-54000
-0.02%
0.01%
SBI Arbitrage Opportunities Fund Direct-Growth
0.03%
50400
0.01%
0.02%
ICICI Prudential Children's Fund Direct-Growth
0.00%
-50000
-0.36%
0.00%
Tata Arbitrage Fund Direct - Growth
0.01%
-29700
-0.02%
0.00%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.02%
26100
0.01%
0.01%
UTI Arbitrage Fund Direct-Growth
0.03%
25200
0.02%
0.03%
Nippon India Arbitrage Fund Direct-Growth
0.00%
-25200
-0.02%
0.00%
Union Arbitrage Fund Direct - Growth
0.00%
-17100
-0.56%
0.00%

Technical Indicators

RSI(14)
Neutral
32.09
ATR(14)
Less Volatile
18.02
STOCH(9,6)
Oversold
10.60
STOCH RSI(14)
Neutral
21.14
MACD(12,26)
Bearish
-2.43
ADX(14)
Weak Trend
19.35
UO(9)
Bullish
29.05
ROC(12)
Downtrend And Accelerating
-4.88
WillR(14)
Oversold
-95.10
Bearish
3
Neutral
4
Bullish
2

About Zydus Life Science

Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years, -2 days)
Website
https://www.zyduscadila.com
Chairperson NamePankaj R Patel
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104